アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 300 mg - isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculos with isoniazid, or any other medication, is inadequate therapy. isoniazid is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. persons with human immunodeficiency virus (hiv) infection (≥ 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin- negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therapy who have hiv infection should have a minimum of 12

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

bryant ranch prepack - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 100 mg - isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): - persons with human immunodeficiency virus (hiv) infection (greater than or equal to 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therapy who have

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 300 mg - isoniazid tablets, usp are recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. isoniazid tablets, usp are recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): - persons with human immunodeficiency virus (hiv) infection (greater than or equal to 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therap

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 50 mg in 5 ml - isoniazid oral solution is recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid or any other medication is inadequate therapy. isoniazid oral solution is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): - persons with human immunodeficiency virus (hiv) infection (greater than or equal to 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therapy

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - pyridoxine hydrochloride 100 mg/2 ml - solution for injection; oral solution - 100 mg/2 ml - pyridoxine hydrochloride 100 mg - pyridoxine (vit b6)

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - pyridoxine hydrochloride 250 mg/2 ml - solution for injection; oral solution - 250 mg/2 ml - pyridoxine hydrochloride 250 mg - pyridoxine (vit b6)

ケニア - 英語 - Pharmacy and Poisons Board

isoniazid bp - dispersible tablet - isoniazid bp 100mg - isoniazid

ケニア - 英語 - Pharmacy and Poisons Board

isoniazid - tablet - isoniazid 300mg - isoniazid

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; gelatin; calcium hydrogen phosphate dihydrate; maize starch; ethylcellulose; sorbitol; titanium dioxide; macrogol 6000 - indications as at 04 jan 2002 : oral administation : myambutol is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - myambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months for example, myambutol plus isoniazid plus rifampicin or myambutol plus isoniazid plus streptomycin then continuing with a two drug regimen such as myambutol plus isoniazid or myambutol plus rifampicin. in patients who have received previous antituberculosis therapy, mycobacterial resistance to other durgs used in initial therapy is frequent. consequently, in such retreatment cases myambutol should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with myambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been use in multiple drug regimens. alternating drug regimens have also been utilised.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride - oral tablet - 20mg ; 2mg ; 2mg ; 5mg